AbCellera Biologics Inc vs iShares MSCI ACWI ETF — how do they compare? AbCellera Biologics Inc trades at $8.93 (market cap $2.85B), while iShares MSCI ACWI ETF trades at $161.26. The key difference: iShares MSCI ACWI ETF is trading nearer its 52-week high, AbCellera Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | ACWI | |
|---|---|---|
Market Cap | $2.85B | — |
Sector | Health | — |
52-Week High | $9.76 | $161.44 |
52-Week Low | $2.78 | $132.04 |
Enterprise Value | $2.45B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ACWI (iShares MSCI ACWI ETF) trades at $161.44, up 0.84% with a bullish technical signal from moving averages, though oscillators show caution. The ETF benefits from strong global earnings growth and a forward P/E of 15.5x as of Seeking Alpha on July 7, 2026. Recent institutional activity includes Bank of New York Mellon adjusting its stake, reflecting ongoing investor interest in global equity exposure, particularly in technology sectors.
The outlook for ACWI is supported by robust EPS growth and technical momentum, but risks include market volatility and sector concentration. Investors may find opportunity in its diversified global holdings, though overbought conditions near resistance at $162 warrant monitoring for pullbacks to support at $160.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →